The influence of HLA donor-recipient compatibility on the recurrence of HBV and HCV hepatitis after liver transplantation.

cytes during anti-T lymphocyte therapy might define a subgroup of transplant recipients at risk for PrLD. Monitoring the percentage of CD19+ lymphocytes during anti-T cell therapy allowed early modification of the immunosuppressive and antiviral regimen. apparently with favorable alteration in the lymphoproliferative process. This preliminary experience suggests that reduction in overall immunosuppression with concomitant initiation of antiviral therapy for patients with elevated levels of circulating CD19+ B lymphocytes may positively impact the natural history of PJ'LD. Although more extensive evaluation, including larger clinical trials, must validate our findings, peripheral B lymphocyte analysis using mAb and flow cytometry may represent an effective screening strategy . of patients at risk for PJ'LD.